Obstetrics & Gynecology Science

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer

Yun-Ji Kim, Inha Lee, Young Shin Chung, EunJi Nam, Sunghoon Kim, Sang-Wun Kim, Young Tae Kim, Jung-Yun Lee

Obstet Gynecol Sci. 2018;61(2):227-234. Published online February 5, 2018
DOI: https://doi.org/10.5468/ogs.2018.61.2.227

Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer

Yun-Ji Kim, Inha Lee, Young Shin Chung, EunJi Nam, Sunghoon Kim, Sang-Wun Kim, Young Tae Kim, Jung-Yun Lee

Obstetrics & Gynecology Science. 2018;61(2):227

Link1 Link2 Link3

Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer

Elisabetta Sanna, Luciana Tanca, Cristina Cherchi, Giulia Gramignano, Sara Oppi, Maria Gloria Chiai, Antonio Macciò, Clelia Madeddu

Diagnostics. 2021;11(7):1298

Link1

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer

Agnieszka Badora-Rybicka, Elżbieta Nowara, Danuta Starzyczny-Słota

ESMO Open. 2016;1(2):e000039

Link1 Link2 Link3

Neutrophil-to-Lymphocyte Ratio and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant Chemotherapy

Michalis Liontos, Angeliki Andrikopoulou, Konstantinos Koutsoukos, Christos Markellos, Efthymia Skafida, Oraianthi Fiste, Maria Kaparelou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Flora Zagouri

. 2021;

Link1 Link2

Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy

M. Liontos, A. Andrikopoulou, K. Koutsoukos, C. Markellos, E. Skafida, O. Fiste, M. Kaparelou, N. Thomakos, D. Haidopoulos, A. Rodolakis, M. A. Dimopoulos, F. Zagouri

Journal of Ovarian Research. 2021;14(1):

Link1

Link2 Link3

Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy

R. Eitan, L. Salman, G. Sabah, A. Jakobson-Setton, O. Raban, E. Yeoshoua, D. Tsoref

Gynecologic Oncology. 2019;154:269-270

Link1 Link2

Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study

Yi Chen, Kai Chen, Xiaoyun Xiao, Yan Nie, Shaohua Qu, Chang Gong, Fengxi Su, Erwei Song

BMC Cancer. 2016;16(1):

Link1

Link2 Link3 Link4

Dynamic change in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy is associated with pathologic response in pancreatic cancer

P. Sharma, I. Silva, A. Collier, J. Kronenfeld, M. Seaton, A. Dosch, D. Franceschi, A. Livingstone, N. Merchant, J. Datta

HPB. 2021;23:S480

Link1 Link2

Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis

Xiaomin Li, Qiuwen Tan, Hongjiang Li, Xiaoqin Yang

Cancer Management and Research. 2021;Volume 13:5889-5898

Link1 Link2

Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment

Wendy Muñoz-Montaño, Paula Cabrera-Galeana, Alberto Alvarado-Miranda, Cynthia Villarreal-Garza, Alejandro Mohar, Alejandro Olvera, Enrique Bargallo-Rocha, Fernando Lara-Medina, Oscar Arrieta

Clinical Breast Cancer. 2020;20(4):307-316.e1

Link1 Link2